Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK501495PMID: 30000555
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 218620-50-9
Drug Levels and Effects
Summary of Use during Lactation
Limited data indicate that pegvisomant is poorly excreted into breastmilk. Because pegvisomant is not orally absorbed, it is unlikely to adversely affect the breastfed infant. Polyethylene glycol is not excreted into breastmilk.[1]
Drug Levels
A woman was being treated during pregnancy for acromegaly with subcutaneous pegvisomant at a dosage that was progressively escalated from 15 mg to 25 mg daily during the course of pregnancy, and presumably postpartum. At an unreported time postpartum, pegvisomant was not detectable (<50 mcg/L) in breastmilk. The patient's breastmilk growth hormone concentration was 0.6 mcg/L compared to <0.1 mcg/L in 3 breastmilk samples from normal healthy mothers.[2]
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
A woman with acromegaly was treated with lanreotide Autogel 120 mg monthly, cabergoline 2 mg weekly and pegvisomant 80 mg weekly. She breastfed (extent not stated) her infant and they were followed for 12 years. Her child had normal growth and development.[3]
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
References
- 1.
- Clowse ME, Förger F, Hwang C, et al. Minimal to no transfer of certolizumab pegol into breast milk: Results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis. 2017;76:1890–6. [PMC free article: PMC5705850] [PubMed: 28814432]
- 2.
- Brian SR, Bidlingmaier M, Wajnrajch MP, et al. Treatment of acromegaly with pegvisomant during pregnancy: Maternal and fetal effects. J Clin Endocrinol Metab. 2007;92:3374–7. [PubMed: 17595256]
- 3.
- Popescu AD, Carsote M, Valea A, et al. Approach of acromegaly during pregnancy. Diagnostics (Basel). 2022;12:2669. [PMC free article: PMC9689290] [PubMed: 36359512]
Substance Identification
Substance Name
Pegvisomant
CAS Registry Number
218620-50-9
Drug Class
Breast Feeding
Milk, Human
Human Growth Hormone Analogues and Derivatives
Growth Hormone Receptor Antagonists
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- Review Peginterferon Alfa.[Drugs and Lactation Database (...]Review Peginterferon Alfa.. Drugs and Lactation Database (LactMed®). 2006
- Review Teicoplanin.[Drugs and Lactation Database (...]Review Teicoplanin.. Drugs and Lactation Database (LactMed®). 2006
- Review Butorphanol.[Drugs and Lactation Database (...]Review Butorphanol.. Drugs and Lactation Database (LactMed®). 2006
- Review Miglitol.[Drugs and Lactation Database (...]Review Miglitol.. Drugs and Lactation Database (LactMed®). 2006
- Review Octreotide.[Drugs and Lactation Database (...]Review Octreotide.. Drugs and Lactation Database (LactMed®). 2006
- Pegvisomant - Drugs and Lactation Database (LactMed®)Pegvisomant - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...